Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
Cancer Medicine · 2023
DOI: 10.1002/cam4.6306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Kazuyuki Numakura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with mRCC. Therefore, this investigation aimed to evaluate the clinical implication of PRD in patients with mRCC to select better candidates in whom NIVO+IPI can be initiated as first‐line therapy.
Methods
This multi‐institutional retrospective cohort study used data collected between August 2015 and January 2023. In total, 120 patients with mRCC treated with NIVO+IPI were eligible. Associations between immune‐related adverse events and progression‐free survival, overall survival (OS), and objective response rate were analyzed. The relationship between other clinical factors and outcomes was also evaluated.
Results
The median observation period was 16 months (interquartile range, 5–27). The median age at NIVO+IPI initiation was 68 years in the male‐dominant population ( n = 86, 71.7%), and most patients had clear cell histology ( n = 104, 86.7%). PRD was recorded in 26 (23.4%) of 111 investigated patients during NIVO+IPI therapy. Patients who experienced PRD showed worse OS (hazard ratio: 4.525, 95% confidence interval [CI]: 2.315–8.850, p < 0.001). Multivariable analysis showed that lymph node metastasis (LNM) (odds ratio: 4.274, 95% CI: 1.075–16.949, p = 0.039) was an independent risk factor for PRD.
Conclusions
PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first‐line therapy and might indicate that a candidate will not benefit from NIVO+IPI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Anatomy, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Urology, Ageo Central General Hospital, Ageo, Japan.
ORCID-Profile: Kazuyuki Numakura, Shintaro Narita
Zitieren
APA
Numakura, K., Sekine, Y., Hatakeyama, S., Muto, Y., Sobu, R., Kobayashi, M., Sasagawa, H., Kashima, S., Yamamto, R., Nara, T., Akashi, H., Tabata, R., Sato, S., Saito, M., Narita, S., Ohyama, C., & Habuchi, T. (2023). Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6306
Vancouver
Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, et al. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6306
BibTeX
@article{Numakura2023,
author = {Numakura, Kazuyuki and Sekine, Yuya and Hatakeyama, Shingo and Muto, Yumina and Sobu, Ryuta and Kobayashi, Mizuki and Sasagawa, Hajime and Kashima, Soki and Yamamto, Ryohei and Nara, Taketoshi and Akashi, Hideo and Tabata, Ryuji and Sato, Satoshi and Saito, Mitsuru and Narita, Shintaro and Ohyama, Chikara and Habuchi, Tomonori},
title = {Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6306}
}
EUVIMED